PDCD1 and cancer: In a clinical case report, for the first time, the combination of the anti-PD-1 antibody nivolumab (3 mg·kg−1 body weight every 2 weeks) and the anti-CTLA4 antibody ipilimumab (1 mg·kg−1 body weight every 6 weeks) was administered to a patient with HNSCC.82 After 3 weeks of treatment with the drugs, computerized tomography (CT) examination of the patient showed a cancer response 4 months after surgery.